Modulation of Alloimmunity by Heat Shock Proteins

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Borges, Thiago J., Benjamin J. Lang, Rafael L. Lopes, and Cristina Bonorino. 2016. “Modulation of Alloimmunity by Heat Shock Proteins.” Frontiers in Immunology 7 (1): 303. doi:10.3389/fimmu.2016.00303. http://dx.doi.org/10.3389/fimmu.2016.00303.

Published Version
doi:10.3389/fimmu.2016.00303

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002597

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Modulation of Alloimmunity by Heat Shock Proteins

**Thiago J. Borges**, **Benjamin J. Lang**, **Rafael L. Lopes** and **Cristina Bonorino**

1 Faculdade de Biociências e Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 2 Department of Radiation Oncology, Center for Life Sciences, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

The immunological mechanisms that evolved for host defense against pathogens and injury are also responsible for transplant rejection. Host rejection of foreign tissue was originally thought to be mediated mainly by T cell recognition of foreign MHC alleles. Management of solid organ transplant rejection has thus focused mainly on inhibition of T cell function and matching MHC alleles between donor and host. Recently, however, it has been demonstrated that the magnitude of the initial innate immune responses upon transplantation has a decisive impact on rejection. The exact mechanisms underlying this phenomenon have yet to be characterized. Ischemic cell death and inflammation that occur upon transplantation are synonymous with extracellular release of various heat shock proteins (Hsps), many of which have been shown to have immune-modulatory properties. Here, we review the impact of Hsps upon alloimmunity and discuss the potential use of Hsps as accessory agents to improve solid organ transplant outcomes.

**Keywords**: Hsps, transplantation, alloimmunity, dendritic cells, immune regulation

**INTRODUCTION**

During organ transplantation, tissues are injured as a consequence of ischemia and reperfusion. Upon organ harvest, ischemia ensues and continues during organ preservation. Reperfusion happens upon anastomosis of graft vessels. Ischemia–reperfusion injury (IRI) induces cell death by necrosis and apoptosis leading to production of molecules denominated damage-associated molecular pattern (DAMPS) or alarmins (1). These are self, intracellular molecules, which are released by injured or necrotic cells under pathological conditions. In the extracellular environment, they can interact with and activate innate immune cells, acting as “danger signals” (2, 3). Resident macrophages and dendritic cells (DCs) are sensitive to DAMPs signals. These cells sense initial ischemic insults through pattern recognition receptors (PRRs). The engagement PRRs, including toll-like receptors (TLRs) and scavenger receptors (SRs), trigger intracellular signaling cascades that culminate in activation of transcription factors, which coordinate production of inflammatory cytokines and chemokines, upregulation of MHC and co-stimulatory molecules. DCs are the major antigen-presenting cells (APCs) and once activated in tissues, migrate to draining lymph nodes, and stimulate alloreactive T cell responses. DCs have to deliver three signals for optimal activation of T cells: (i) the expression of peptide:MHC complexes that will be recognized by the T cell receptor (TCR); (ii) co-stimulatory molecules; and (iii) cytokines that will shape T cell-mediated responses. Macrophages are also important contributors to IRI-induced inflammation and produce immune-stimulatory cytokines TNF-α, IL-1β, IL-6, and MCP-1, and chemokines which facilitate recruitment of alloreactive T-cells to the graft site (4, 5). While alloantigen-specific T cells are responsible for subsequent organ rejection and destruction, this outcome is very much shaped...
by the local inflammatory state of the graft site (6). Thus, allo-
reactive immune responses result from activation of cellular
components of both innate and adaptive immunity (7).

To improve the longevity of solid organ transplants, it is
desirable to develop methods to limit IRI-induced inflamma-
tion and the ensuing alloreactive immune response. This review
will discuss how heat shock proteins (Hsps) can modulate
inflammatory and allogeneic immune responses, and how
this can be harnessed to manage graft rejection in solid organ
transplantation.

THE HEAT SHOCK RESPONSE AND
CYTOPROTECTIVE PROPERTIES OF Hsps

The heat shock response is universal and conserved from bacteria
to mammals. It can be triggered by a range of protein-damaging
conditions that affect organisms such as heat, anaerobiosis/
hypoxia, oxidative stress, inflammation, fever, and infection.
Activation of the heat shock response is marked by upregulation
of various Hsps. Under stress conditions, intracellular Hsps
prevent protein aggregation, refold damaged proteins, and target
damaged proteins for degradation. Under non-stress conditions,
Hsps assist the folding of recently synthesized proteins, the trans-
location of proteins between organelles, and also regulate the cell
cycle. These homeostatic functions of intracellular Hsps support
proteome integrity and thereby promote cell viability. In addition,
Hsps, such as Hsp70 and Hsp27, have been shown to negatively
regulate multiple apoptotic signaling events including mito-
chondrial cytochrome c release (Hsp27), mitochondrial release
of Smac (Hsp27), nuclear translocation of apoptosis-inducing
factor (AIF) (Hsp70), and cleavage of procaspase 3 (Hsp70)
(8–12). Hsps are conventionally grouped into families according
to their molecular weight (e.g., Hsp40, Hsp70, and Hsp100) (13,
14). Functional cooperation exists between family members;
however, individual Hsp species perform distinct functions that
can also be context dependent. In the context of IRI and organ
transplantation, increased Hsp levels have been associated with
cytoprotection, improvement of organ viability, and function
after ischemia–reperfusion (15).

INTRACELLULAR Hsps PROTECT
ALLOGRAFTS FROM
ISCHEMIA–REPERFUSION INJURY
AND IMPROVE GRAFT SURVIVAL

Increased levels of Hsps in transplant organ cells either by treat-
ment or genetic manipulation have been demonstrated to be ben-
eficial for transplant longevity (16). Hsps promote refolding of
proteins denatured due to IRI, protecting cells from IRI-induced
death. Hsp70 has been proposed to be the most potent anti-
apoptotic mediator inside the cell (17). Heat pre-conditioning of
organs prior to transplant upregulates the expression of Hsps and
prevents tissue damage from IRI by different mechanisms (18).
Hsps’ cytoprotective capacity was also demonstrated in organs
that were genetically modified to overexpress these proteins.
Hearts from mice overexpressing Hsp27 induction correlated
with increased survival when transplanted in fully MHC-
mismatched hosts (16). These hearts presented reduced caspase
activation after subjection of ischemic/reperfusion conditions.
In addition to heat, hypoxic pre-conditioning seems to reduce
ischemic renal failure through a HIF-α/Hsp70 signaling pathway
(19). This literature has been extensively reviewed in previous
works (15, 20, 21).

Hsps CAN PROTECT FROM IRI BY
MODULATING INFLAMMATION

Recently, several studies have highlighted a previously overlooked
importance of innate cells in shaping T cell-mediated responses
to alloantigens (5). Indeed, IRI and the subsequent intra-organ
activation of innate cells have been shown to markedly enhance
alloimmunity, contributing to poorer long-term outcomes and
graft function. For example, delayed graft function (DGF) is a
complication that occurs very early after the transplant procedure
and results from a previous intense ischemic injury. Kidney trans-
plant patients with DGF have a higher risk to graft loss (22). Thus,
strategies and treatments that prevent or decrease the activation
of APCs by the released of ischemic-derived DAMPs could result
in diminished alloimmunity and improve both early and late graft
function (23).

During IRI, an important DAMP released by injured cells
is the nucleotide adenosine triphosphate (ATP). Extracellular
ATP (eATP) is recognized by purinergic receptors expressed by
immune cells. Once eATP engages such receptors, it can trigger
innate inflammatory responses and activation and prolifera-
tion of T cells. This can lead to further inflammation and cell
damage, contributing to rejection [extensively reviewed in Ref.
(24, 25)]. Additionally, high-mobility group box 1 (HMGB1)
can also be released from dying cells. HMGB1 has been reported
to be involved in IRI. HMGB-1 can activate APCs through TLR2 and TLR4 (26), as well as the receptor for advanced
glycation end products (RAGE) (27), triggering anti-donor T
cell responses (28).

Heat shock proteins have been suggested to act as DAMPs
(29). Initial observations demonstrated that Hsps are elevated in
transplanted organs, and Hsp-reactive T cells do infiltrate organs
undergoing rejection (30). This raised the initial idea that such
proteins play a crucial role as immunogenic antigens during
alloimmune responses (15). Hsps are among many intracellular
proteins that are released to the extracellular environment as a
consequence of cell death during IRI. This is one reason why many
consider Hsps to be DAMPS. Another reason is that extracellular
isforms of Hsps were reported by some studies to interact with
TLRs and SRs and trigger inflammatory responses (31).

Aside from being passively released, Hsps can reach the
extracellular milieu through different active pathways. Hsp70
can be exported by an active non-classical secretory pathway,
which cannot be blocked by inhibitors of the ER–Golgi pathway
(32). Also, Hsp70 can be released by a lysosome–endosome
mechanism, similar to IL-1β secretion (33), and a pathway
involving secretory-like granules (34). Finally, Hsp70 can be
secreted by a mechanism involving the insertion into exosome
membranes (35).
Thus, a scenario in which Hsps are found extracellularly during transplantation is likely, independently of passive or active release. More recent studies suggested that extracellular Hsps in transplants play additional immune roles – triggering anti-inflammatory responses and acting as immune modulators. In contrast to the DAMPs hypothesis, it was proposed that Hsps could belong to a group of molecules denominated resolution-associated molecular patterns (RAMPs) (36). RAMPs are released from necrotic and damaged cells, and when they reach the extracellular environment, will exert anti-inflammatory and regulatory effects over immune cells.

Resolution-associated molecular patterns are proposed to counterbalance acute inflammation and restore immune homeostasis by modulating innate cells. After tissue damage, they can modulate acute inflammation by inducing the production of IL-10 (36). IL-10 has powerful anti-inflammatory and immune suppressive properties. It can modulate DCs activation and differentiation, inhibits the release of inflammatory cytokines by T cells, APCs, and NK cells, and impairs cytotoxic ability of CD8 T cells (37). The alpha B-crystallin (αBC) protein is considered a RAMP. Mice deficient for this protein have an exacerbated form of experimental autoimmune encephalomyelitis (EAE). Administration of αBC to mice with EAE reduces severity disease scores (38). Interestingly, and maybe not coincidentally, αBC is a chaperone, and a member of the small Hsps group. The induction of IL-10 by other Hsps, such as Hsp70 (39), Hsp60 (40), and BiP (41), is well documented and has been reviewed elsewhere.

**TRANSPANT OF ORGANS GENETICALLY MODIFIED TO OVEREXPRESS Hsps GENERATE LESS INFLAMMATION**

A member of the Hsp70 family that has immunomodulatory effects and acts as a RAMP is the endoplasmic reticulum (ER) protein GRP78 or BiP (38). When islet cells overexpressing GRP78 were transplanted in fully MHC-mismatched hosts, they presented decreased cell death, prolonged survival, and were less immunogenic compared with controls (42). In a murine cardiac transplant model, transgenic Hsp27 overexpression increased allograft survival. Hsp27tg-derived hearts exhibited reduced T cell-induced apoptosis ex vivo and stimulated a reduced allogeneic inflammatory response compared with hearts transplanted from littermate controls (16). Markers for infiltrating T cells were reduced within transplanted hearts from Hsp27tg mice, and this was coupled with less production of IFN-γ day 5 post-transplant and increased IL-4 at day 2. In other inflammatory models, overexpression of Hsps has also been shown to be beneficial not only due to their pro-survival roles but also by dampening inflammation. Overexpression of Hsp70 in transgenic (Tg) mice has been shown to protect animals from neuroinflammation (43). Hsp70 overexpression can also induce neuroprotection from stroke and traumatic brain injury (44, 45). Consistent with Hsp70 possessing protective properties against tissue injury, Hsp70 Tg mice were found to have protection from inflammatory colitis and pulmonary fibrosis in respective models compared with their wild-type counterparts (46, 47).

In summary, increased levels of Hsps can be beneficial through the prevention of cell death, precluding the release of DAMPs. It is also possible that in HspTg mice, after tissue damage is induced by transplantation, the concentration of extracellular Hsps released from damaged cells is higher, resulting in induction of tolerogenic responses and the dampening of inflammation.

**Hsp PEPTIDES AS ANTIGENS FOR Treg CELLS**

Regulatory T cells (Tregs) can suppress excessive effector immune responses that are harmful to the host (48). Tregs can actively suppress innate and adaptive inflammatory immune responses through the production of the anti-inflammatory cytokines IL-10 and/or TGF-β (49). Induction or administration of Tregs during transplantation is a promising approach for the management of allograft rejection (50). Although the peptide ligands for Tregs have not extensively been characterized, several studies have reported that they recognize self-peptides bound to MHC class II molecules (51). Tregs originate in the thymus (Ttregs) but can also be induced at peripheral sites (pTregs) (52). For example, pTregs can be generated in a tolerogenic microenvironment by interacting with DCs producing anti-inflammatory cytokines and low levels of MHC II and co-stimulatory molecules (53).

Recently, it was shown that heat pre-conditioning of the organ had protective effects in acute kidney injury induced by IRI, and that protection was mediated by a direct immunomodulatory response of Hsp70-specific Tregs (54).

**MODULATION OF ALLOGRAFT REJECTION BY EXTRACELLULAR Hsps**

In addition to benefits for transplant organs conferred by increased intracellular Hsp levels, a number of studies have now demonstrated various extracellular Hsps to also extend graft survival. For example, subcutaneous treatment of recipients prior to transplant with a single dose of full-length murine Hsp60 or with two of its peptides (p12 and p277) was found to prolong skin graft acceptance (55). Interestingly, no improvement in skin allograft survival was observed when recipients were treated with an Hsp60 peptide from Mycobacterium tuberculosis (55). The authors suggested the differential effect between these Hsp60 species was likely due to a shift from an IFN-γ- to IL-10-producing phenotype in self-Hsp60-specific T cells, a shift which was not induced by treatment with mycobacterial Hsp60 (56). Consistent with skin graft protection conferred by mouse Hsp60 peptide administration, intranasal pre-treatment with encapsulated human Hsp60-derived peptide (p277) increased skin graft survival in two minor mismatched mice models (57). In this study, treatment with human Hsp60 also induced production of the anti-inflammatory cytokine IL-10. Together the findings from these studies indicate that Hsp-mediated extension of graft survival may be closely related to IL-10 induction.

Heat shock protein 10 is an Hsp60 co-chaperone and was first described as early pregnancy factor (EPF) (58). This protein is
Beneficial effects of Hsps during transplantation. The upregulation of intracellular Hsps (iHsps) can protect cells from injury with a diminished release of DAMPs, decreased innate inflammation and less alloreactive T cell activation. The presence (in high concentrations) or administration of extracellular Hsps (eHsps) can also trigger immune-regulatory pathways on innate cells, favoring the generation of Tregs.

Heat shock protein 70 (DnaK) from \textit{M. tuberculosis} can improve graft survival in two different models of skin allografts. First, when the allogeneic B16F10 melanoma cells (H-2b/I-Ab) are subcutaneously injected in BALB/c hosts (H-2d/I-Ad), they are rejected due to MHC disparity. However, when those cells were injected in the presence of DnaK, they could form tumors in the hosts (60). \textit{In situ} analysis demonstrated a tolerogenic environment with an increased infiltration of Tregs in DnaK-treated tumors, and depletion of Tregs abrogated DnaK-mediated tumor protection. Extracellular DnaK treatment of bone marrow-derived macrophages (BMMs) was also found to promote the immunosuppressive M2-like macrophage phenotype and favor tumor growth in a murine melanoma model (61). Together, these studies demonstrated DnaK to have immunosuppressive effects upon multiple cell types. To exclude that the extended graft acceptance observed upon DnaK pre-treatment was due to other tumor mechanisms of immune evasion, we tested whether DnaK pre-treatment \textit{in situ} impacted upon alloreactive responses in a fully MHC-mismatched skin graft model. We observed that DnaK-treated allografts had a significant increase in survival when compared with controls and in addition, this effect was dependent on Tregs (60, 62).

In addition to Hsp60 and Hsp70 family members, Hsp90 proteins have also been shown to have protective properties. For example, subcutaneous treatment with mouse gp96 was shown to delay skin allograft rejection in minor and major mismatch models (63). In another study, intradermal treatment of heart transplanted rats with high doses of liver-purified gp96 from the donor strain prolonged graft survival. Treatment with gp96 appeared to improve cardiac graft function immediately post-transplantation. Interestingly, this treatment did not have an effect on graft survival if gp96 was derived from the host strain (64). The author’s proposed gp96 acted upon innate cells such as APCs, which led to a reduced T cell response and delayed rejection. As the delayed rejection effect was only observed when donor strain-derived gp96 was used, we would suggest that it was donor cells that were subject to the immune-suppressive properties of gp96. The author did not exclude the gp96 effects upon graft longevity could be due to its wound-healing properties (64).

CONCLUSION AND PERSPECTIVES

There is now substantial evidence to demonstrate the immunosuppressive potential of Hsps. These studies indicate that the anti-inflammatory properties of Hsps warrant further investigation into Hsp-based treatments for contexts in which repression of immune responses is desirable. As discussed here, Hsp treatments have been effective agents to inhibit alloimmunity and extend solid organ transplant survival in mice. One could hypothesize Hsp treatments that promote a tolerogenic environment to also have therapeutic applications for various autoimmune and inflammatory diseases.

It remains to be seen how universal the application of immune-regulatory properties of Hsps can be applied to transplants of different cells and tissues. It is also important to note that Hsps were reported to amplify inflammatory (31) and immune responses to tumor antigens (65). Thus, the impact of Hsps upon the resulting immune and inflammatory response currently appears to be very much context dependent (31).

In solid organ transplantation contexts, however, most studies have indicated higher levels of intracellular and extracellular Hsps extend graft survival. This is likely due to a combination of the cytoprotective properties of Hsps enabling better survival found in pregnant women’s sera, and was described to be immunosuppressive, involved in fetus tolerance (58). The subcutaneous \textit{in situ} delivery of recombinant Hsp10 improved skin allograft survival in rats (59). The authors suggested that Hsp10 would inhibit Th1 responses through donor DCs modulation (59).
following IRI and subsequent reduced DAMP release and inflammation as well as the immunomodulatory effect extracellular Hsps have upon multiple cell types including macrophages, T cells, and DCs. The resulting Hsp-induced immuno-biology described has included modulation of APCs to induce tolerogenic responses and regulatory T cells and decreased alloreactive T cell generation (Figure 1).

Thus, ex vivo manipulation of organs before the transplant in order to increase Hsp levels could constitute a promising approach in decreasing initial ischemic damage and inflammation, improving organ survival. Administration of Hsp-derived peptides or ex vivo expansion of Treg with Hsp-derived peptides could be an alternative strategy to improve solid organ outcome. Elicitation of the innate cell subsets and the receptors by which Hsps can specifically interact will be extremely important to optimize Hsp-based therapy design.

**AUTHOR CONTRIBUTIONS**

TB, BL, RL, and CB wrote the paper. TB did the cartoon.

**ACKNOWLEDGMENTS**

This work was supported by FAPERGS (Grant 11/0903-1) and FINEP (Grant 01.08.0600-00). TB is a recipient of post-doctoral fellowship from CAPES/PNPDP program. RL received fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

**REFERENCES**

1. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2007) 81:1–5. doi:10.1189/jlb.0306164
2. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301–5. doi:10.1126/science.1071059
3. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol (2004) 4:469–78. doi:10.1038/nri1372
4. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant (2006) 21:1231–9. doi:10.1093/ndt/gfl047
5. Ochando J, Kwan WH, Ginhoux F, Hutchinson JA, Hashimoto D, Collin M. The mononuclear phagocyte system in organ transplantation. Am J Transplant (2016) 16:1053–69. doi:10.1111/ajt.13627
6. Otterbein LE, Fan Z, Koulmanda M, Throney T, Strom TB. Innate immunity for better or worse govern the allograft response. Curr Opin Organ Transplant (2015) 20:8–12. doi:10.1097/MOT.0000000000000152
7. Farrar CA, Kupiec-Weglinski JW, Saar SH. The innate immune system and transplantation. Cold Spring Harb Perspect Med (2013) 3:a015479. doi:10.1101/cshperspect.a015479
8. Li CY, Lee JS, Ko YG, Kim JJ, Seo JS. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem (2000) 275:25665–71. doi:10.1074/jbc.M906383199
9. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol (2001) 3:839–45. doi:10.1038/ncb0901-839
10. Paul C, Manero F, Gennis S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 as a negative regulator of cytochrome c release. Mol Cell Biol (2002) 22:816–34. doi:10.1128/MCB.22.3.816-834.2002
11. Chauhan D, Li G, Hideshima T, Poddar K, Mitsiades C, Mitsiades N, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood (2003) 102:3379–86. doi:10.1182/blood-2003-05-1417
12. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, et al. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene (2003) 22:6669–78. doi:10.1038/sj.onc.1206794
13. Richter K, Hasbeck M, Buchner J. The heat shock response: life on the verge of death. Mol Cell (2010) 40(2):253–66. doi:10.1016/j.molcel.2010.10.006
14. Verghese J, Abrams J, Wang Y, Morano KA. Biology of the heat shock response and protein chaperones: budding yeast (Saccharomyces cerevisiae) as a model system. Microbiol Mol Cell Biol Rev (2012) 76(2):115–58. doi:10.1128/MMBR.05018-11
15. Pockley AG, Muthana M. Heat shock proteins and allograft rejection. Contrib Nephrol (2005) 148:122–34. doi:10.1159/000086657
16. Seemampillai B, Germack R, Felkin LE, McCormack A, Rose ML. Heat shock protein-27 delays acute rejection after cardiac transplantation: an experimental model. Transplantation (2014) 98:29–38. doi:10.1097/TP.000000000000170
17. Jaatela M. Heat shock proteins as cellular lifeguards. Ann Med (1999) 31:261–71. doi:10.3109/07853899908995889
18. Jones Q, Voegeli TS, Li G, Chen Y, Currie RW. Heat shock proteins protect against ischemia and inflammation through multiple mechanisms. Inflamm Allergy Drug Targets (2011) 10:247–59. doi:10.2174/187152811796117726
19. Yeh CH, Hsu SP, Yang CC, Chien CT, Wang NP. Hypoxic preconditioning reinforces HIF-alpha-dependent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy. Life Sci (2010) 86:115–23. doi:10.1016/j.lfs.2009.11.022
20. O’Neill S, Ross JA, Wigmorre SJ, Harrison EM. The role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney. Expert Opin Investig Drugs (2012) 21:1535–48. doi:10.1517/13543784.2012.713939
21. O’Neill S, Harrison EM, Ross JA, Wigmorre SJ, Hughes J. Heat shock proteins and acute ischaemic kidney injury. Nephron Exp Nephrol (2014) 126:167–74. doi:10.1155/2009/363323
22. Yarlagadda SG, Coca SG, Formica RN, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant (2009) 24:1039–47. doi:10.1093/ndt/gfn667
23. Solhiou Z, Ather H, Xu Q, Abdi R. Emerging therapies targeting intra-orga- n organ inflammation in transplantation. Am J Transplant (2015) 15:305–11. doi:10.1111/ajt.13073
24. Vertani A, Tezza S, Fontin C, Vinser G, Pileggi A, Chandraker A, et al. The purinergic system in allotransplantation. Am J Transplant (2014) 14:507–14. doi:10.1111/ajt.12567
25. Zeiser R, Robson SC, Vaikunthanathan T, Dworak M, Burnstock G. Unlocking the potential of purinergic signaling in transplantation. Am J Transplant (2016). doi:10.1111/ajt.13801
26. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 26:174–9. doi:10.1097/01.shk.0000225404.51320.82
27. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 61:6–9. doi:10.1111/j.0300-9475.2005.01534.x
28. Land GW. Emerging role of innate immunity in organ transplantation part II: potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transplant Rev (Orlando) (2012) 26:73–87. doi:10.1016/j.trre.2012.02.003
29. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 10:826–37. doi:10.1038/nri2873
30. Molterino R, Valdivia L, Pan F, Duquesnoy RJ. Heat shock protein reactivity of lymphocytes isolated from heterotopic rat cardiac allografts. Transplantation (1995) 59:598–604. doi:10.1097/00007890-1995052270-00027
31. Calderwood SK, Gong J, Murshed A. Extracellular HSPs: the complicated roles of extracellular HSPs in immunity. Front Immunol (2016) 7:159. doi:10.3389/fimmu.2016.00159
32. Hightower LE, Guidon PT Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol (1989) 138:257–66. doi:10.1002/jcp.1041380206

33. Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol (2006) 177:7849–57. doi:10.4049/jimmunol.177.11.7849

34. Evdonin AL, Martynova MG, Bystrova OA, Guzhova IV, Margulis BA, Medvedeva ND. The release of Hsp70 from A431 carcinoma cells is mediated by secretory-like granules. Eur J Cell Biol (2006) 85:443–55. doi:10.1016/j.ejcb.2006.02.008

35. Vega VL, Rodriguez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, et al. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol (2008) 180:4299–307. doi:10.4049/jimmunol.180.6.4299

36. Shields AM, Panayi GS, Corrigall VM. Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 165:292–300. doi:10.1111/j.1365-2249.2011.04433.x

37. Moore KW, De Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683–765. doi:10.1146/annurev.immunol.19.1.683

38. Shields AM, Thompson SJ, Panayi GS, Corrigall VM. Pro-resolution immunological networks: binding immunoglobulin protein and other resolution-associated molecular patterns. Rheumatology (Oxford) (2012) 51:781–8. doi:10.1093/rheumatology/ker412

39. Borges TJ, Wieten L, Van Herwijnen MJ, Broere F, Van Der Zee R, Bonorino C, et al. The anti-inflammatory mechanisms of Hsp70. Front Immunol (2012) 3:95. doi:10.3389/fimmu.2012.00095

40. Quintana FJ, Cohen IR. The HSP60 immune system network. Trends Immunol (2010) 32:89–95. doi:10.1016/j.it.2010.11.001

41. Shields AM, Panayi GS, Corrigall VM. A new-age for biologic therapies: long-term drug-free therapy with BiP? Front Immunol (2012) 3:17. doi:10.3389/fimmu.2012.00017

42. Kim N, Kim YJ, Yenari MA. Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury. Inflammopharmacology (2012) 20(3):177–85. doi:10.1007/s10787-011-0115-3

43. Yenari MA, Giffard RG, Sapolsky RM, Steinberg GK. The neuroprotective potential of heat shock protein 70 (HSP70). Mol Med Today (1999) 5:525–31. doi:10.1016/S1357-4310(99)01599-3

44. Zheng Z, Kim YJ, Ma H, Lee JE, Yenari MA. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab (2008) 28:53–63. doi:10.1038/jcbfm.9600502

45. Tanaka K, Namba T, Arai Y, Fujimoto M, Adachi H, Sobue G, et al. Genetic evidence for a protective role for heat shock factor 1 and heat shock protein 70 against colitis. J Biol Chem (2007) 282:23240–52. doi:10.1074/jbc.M704801200

46. Tanaka K, Tanaka Y, Namba T, Azuma A, Mizushima T. Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem Pharmocol (2010) 80:920–31. doi:10.1016/j.bcp.2010.05.025

47. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133:775–87. doi:10.1016/j.cell.2008.05.009

48. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol (2008) 8:523–32. doi:10.1038/nri2343

49. Tang Q, Bluestone JA. Regulatory T cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 3(11):a015552. doi:10.1101/cshperspect.a015552

50. Simons DM, Picca CC, Oh S, Perrg OA, Atkken M, Erikson J, et al. How specificity for self-peptides shapes the development and function of regulatory T cells. J Leukoc Biol (2010) 88:1099–107. doi:10.1189/jlb.0310183

51. Shevach EM, Thornton AM. Tregs, pTregs, and iTregs: similarities and differences. Immunol Rev (2014) 259:88–102. doi:10.1111/imr.12160

52. Swiger U, Rozman P. Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation. J Leukoc Biol (2014) 95:53–69. doi:10.1189/jlb.0613336

53. Kim MG, Jung Cho E, Won Lee J, Sook Ko Y, Young Lee H, Jo SK, et al. The heat-shock protein-70 induced renoprotective effect is partially mediated by CD4+ CD25+ Foxp3 + regulatory T cells in ischemia/reperfusion-induced acute kidney injury. Kidney Int (2014) 85:62–71. doi:10.1038/kli.2013.277

54. Birk OS, Gur SL, Elias D, Margalit R, Mor F, Carmi P, et al. The 60-kDa heat shock protein modulates allograft rejection. Proc Natl Acad Sci U S A (1999) 96:5159–63. doi:10.1073/pnas.96.9.5159

55. Elias D, Meinlin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes (1997) 46:758–64. doi:10.2337/db9.4.5.758

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2016 Borges, Lang, Lopes and Bonorino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.